Second Heidelberg Thoracic Oncology Symposium on the Diagnosis and Treatment of Pleural Mesothelioma-introduction

Lung Cancer

Volumn 45, Issue SUPPL., 2004, Pages S1-

  Thatcher, Nicholas ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MITOMYCIN; NAVELBINE; PEMETREXED; VINBLASTINE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG SCREENING; EARLY DIAGNOSIS; FATALITY; HUMAN; MEDICAL DECISION MAKING; MESOTHELIUM CELL; ORGANIZATION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; STANDARD; VALIDATION PROCESS;

EID: 3142661712     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.003     Document Type: Conference Paper

References (3)

1. Scagliotti G.V., Shin D.M., Kindler H.L. Phase III study of pemetrexed with and without folic acid and vitamin B12 as front line therapy in malignant pleural mesothelioma. J. Clin Oncol. 97:2003;2056-2063
2. Vogelzang N.J., Rustoven J.J., Symanowski J. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin Oncol. 21:2003;2629-2630
3. Girling J.D., Muers M.F., Quian W., Lobban D. Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council. Semin. Oncol. 29:2002;97-101